Pfizer reported detailed Phase 3 TALAPRO-3 results showing TALZENNA (talazoparib) plus XTANDI (enzalutamide) improved radiographic progression-free survival in men with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer. The company said the combination reduced the risk of radiographic progression or death by 52% versus placebo plus XTANDI, with rPFS not reached in the talazoparib arm versus 46 months in the comparator. The company also highlighted durability estimates at three years, reporting higher event-free outcomes across prespecified patient and disease subgroups. Pfizer’s release frames the study as a first consistent rPFS improvement for an established PARP inhibitor plus androgen receptor pathway inhibitor approach in HRR-altered mCSPC. As TALAPRO-3 findings land alongside ASCO presentations and a parallel New England Journal of Medicine publication, the next step for stakeholders is how regulators and clinicians will integrate the data into first-line treatment decisions.